文献速递造血干细胞移植与细胞治疗

29例IKBKG/NEMO亚效突变半合子患者的造血干细胞移植

Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations.
PubMed 文献 · Blood · 2017-07-05

该研究报道了来自11个国家29例携带23种不同IKBKG亚效突变的X连锁外胚层发育不良伴免疫缺陷患者的HSCT前健康状况、移植结局和随访。HSCT后中位随访57个月(范围4-108个月)时总生存率为74%;移植前存在分枝杆菌感染和结肠炎与不良移植结局相关;突变类型似乎不影响结局,移植似乎不能治愈结肠炎。

要点

  • 29例NEMO缺陷患者HSCT后中位随访57个月总生存率为74%。
  • 移植前分枝杆菌感染和结肠炎与不良HSCT结局相关。
  • 相同突变患者结局不同,突变本身似乎不影响移植结局。

核心结论

  • HSCT可使多种IKBKG突变患者的大部分临床特征得到治愈。
  • 移植前分枝杆菌感染和结肠炎与不良HSCT结局相关。
  • 移植似乎不能治愈结肠炎,可能源于上皮屏障的细胞内在异常。

研究设计与样本

  • 报告来自11个国家无亲缘关系家系的29例携带23种不同IKBKG亚效突变患者的HSCT前健康状况、移植结局和临床随访。
  • HSCT供者来源包括HLA相合同胞供者(n=7)、HLA相合无关供者(n=12)、HLA不合无关供者(n=8)和HLA单倍体相合亲缘供者(n=2)。

主要发现

  • 24例患者记录到植入,13例患者发生移植物抗宿主病。
  • 至多7例患者在HSCT后0.2至12个月死亡。
  • NEMO缺陷儿童HSCT后总生存率为74%,HSCT后中位随访57个月(范围4-108个月)。
  • 移植前存在分枝杆菌感染和结肠炎与不良HSCT结局相关。
  • 相同突变患者结局不同,基础突变似乎没有任何影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

X-linked recessive ectodermal dysplasia with immunodeficiency is a rare primary immunodeficiency caused by hypomorphic mutations of the IKBKG gene encoding the nuclear factor κB essential modulator (NEMO) protein. This condition displays enormous allelic, immunological, and clinical heterogeneity, and therapeutic decisions are difficult because NEMO operates in both hematopoietic and nonhematopoietic cells. Hematopoietic stem cell transplantation (HSCT) is potentially life-saving, but the small number of case reports available suggests it has been reserved for only the most severe cases. Here, we report the health status before HSCT, transplantation outcome, and clinical follow-up for a series of 29 patients from unrelated kindreds from 11 countries. Between them, these patients carry 23 different hypomorphic IKBKG mutations. HSCT was performed from HLA-identical related donors (n = 7), HLA-matched unrelated donors (n = 12), HLA-mismatched unrelated donors (n = 8), and HLA-haploidentical related donors (n = 2). Engraftment was documented in 24 patients, and graft-versus-host disease in 13 patients. Up to 7 patients died 0.2 to 12 months after HSCT. The global survival rate after HSCT among NEMO-deficient children was 74% at a median follow-up after HSCT of 57 months (range, 4-108 months). Preexisting mycobacterial infection and colitis were associated with poor HSCT outcome. The underlying mutation does not appear to have any influence, as patients with the same mutation had different outcomes. Transplantation did not appear to cure colitis, possibly as a result of cell-intrinsic disorders of the epithelial barrier. Overall, HSCT can cure most clinical features of patients with a variety of IKBKG mutations.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Miot C, Imai K, Imai C, et al. Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic IKBKG/NEMO mutations. Blood. 2017. PMID: 28679735. doi:10.1182/blood-2017-03-771600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。